Gyros Partners with EMD Millipore to Develop, Manufacture and Commercialize Immunoassay Kits for the Gyrolab™ Platform

16-Jul-2013

  • Simple, automated, nanoliter-scale assays requiring as little as 1uL of sample
  • Ready-to-use kits are fully validated for reliable use in clinical research
  • Accuracy and precision meets or exceeds ELISA performance

 July 15, 2013, Uppsala, Sweden — Gyros AB today announced a partnership with EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, to develop, manufacture and commercialize immunoassay kits for the Gyrolab™ platform. The new, fully validated kits from EMD Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits. Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 560 data points can be generated in a run.

 “We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

Because the Gyrolab platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. Gyrolab assays provide (1) accuracy over a four-log dynamic range, compared to two logs for ELISAs (2) elimination of cross-talk and plate position artifacts and (3) simplified sample prep with reduced matrix interference.

Gyros’ Global Marketing Director Maria Hjortsmark commented: “The Gyrolab platform revolutionizes immunoassays, enabling scientists to analyze a large number of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data.”

For more information on these new kits, please contact Cindy Fry, BS, MBA, EMD Millipore, 636-720-1078, cindy.fry@emdmillipore.com.


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com

www.zymecommunications.com

For EMD Millipore:
Leslie Eisenberg, Feinstein Kean Healthcare, 617-244-3872, leslie.eisenberg@fkhealth.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.